Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years

BACKGROUND: Few clinical studies have focused on the efficacy of lipid-lowering therapies in patients ≥65 years. METHODS: After stabilization on atorvastatin 10 mg, hypercholesterolemic subjects ≥65 years at high/very high risk for CHD and not at LDL-C <1.81 mmol/L (with atherosclerotic vascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Constance, Christian, Ben-Yehuda, Ori, Wenger, Nanette K, Zieve, Franklin, Lin, Jianxin, Hanson, Mary E, Lowe, Robert S, Tershakovec, Andrew M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901347/
https://www.ncbi.nlm.nih.gov/pubmed/24411003
http://dx.doi.org/10.1186/1476-511X-13-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901347/
https://www.ncbi.nlm.nih.gov/pubmed/24411003
http://dx.doi.org/10.1186/1476-511X-13-13

Ejemplares similares